5-(1,2-dihydroxy-2-(pyridin-4-yl)-ethyl)-indan-1-one O-methyloxime | 405554-64-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 5-(1,2-dihydroxy-2-(pyridin-4-yl)-ethyl)-indan-1-one O-methyloxime
• 英文别名: 1-(1-Methoxyimino-2,3-dihydroinden-5-yl)-2-pyridin-4-ylethane-1,2-diol；1-(1-methoxyimino-2,3-dihydroinden-5-yl)-2-pyridin-4-ylethane-1,2-diol
• CAS: 405554-64-5
• 化学式: C₁₇H₁₈N₂O₃
• 分子量: 298.342
• InChiKey: CSJXMGWIFCRNGY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  74.9
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  5-(1,2-dihydroxy-2-(pyridin-4-yl)-ethyl)-indan-1-one O-methyloxime 在 草酰氯 、 二甲基亚砜 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以94%的产率得到1-(1-methoxyiminoindan-5-yl)-2-(pyridin-4-yl)-ethane-1,2-dione
  参考文献：
  名称：

  The identification of potent and selective imidazole-based inhibitors of B-Raf kinase

  摘要：

  A novel triarylimidazole derivative, SB-590885 (33), bearing a 2,3-dihydro-1H-inden-1-one oxime substituent has been identified as a potent and extremely selective inhibitor of B-Raf kinase. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.09.072
• 作为产物：
  描述：

  5-溴茚酮 在 吡啶 、 正丁基锂 、 四丁基氟化铵 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 生成 5-(1,2-dihydroxy-2-(pyridin-4-yl)-ethyl)-indan-1-one O-methyloxime
  参考文献：
  名称：

  The identification of potent and selective imidazole-based inhibitors of B-Raf kinase

  摘要：

  A novel triarylimidazole derivative, SB-590885 (33), bearing a 2,3-dihydro-1H-inden-1-one oxime substituent has been identified as a potent and extremely selective inhibitor of B-Raf kinase. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.09.072

文献信息

• Imidazole derivatives as raf kinase inhibitors
  申请人：——

  公开号：US20040038964A1

  公开（公告）日：2004-02-26

  Novel compounds (I) and their use as pharmaceuticals particularly as Raf kinase inhibitors for the treatment of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine and cardiac hypertrophy wherein Ar is a group of formula a) or b).

  小说化合物（I）及其作为药物的用途，特别是作为Raf激酶抑制剂用于治疗神经创伤性疾病、癌症、慢性神经退化、疼痛、偏头痛和心肌肥大，其中Ar是a)或b)式的基团。
• Imidazole-2-Carboxamide Derivatives as Raf Kinase Inhibitors
  申请人：Dean Kenneth David

  公开号：US20080108615A1

  公开（公告）日：2008-05-08

  The present invention relates to compounds of formula (I): pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, use as Raf Kinase Inhibitors and treatment methods for neurotraumatic diseases and cancer.

  本发明涉及式（I）的化合物：其药学上可接受的盐，相应的制药组合物，用作Raf激酶抑制剂和治疗神经创伤性疾病和癌症的治疗方法。
• IMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS
  申请人：DEAN Kenneth David

  公开号：US20070135433A1

  公开（公告）日：2007-06-14

  Novel compounds and their use as pharmaceuticals particularly as Raf kinase inhibitors for the treatment of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine and cardiac hypertrophy.

  小说化合物及其作为药物的使用，特别是作为Raf激酶抑制剂，用于治疗神经创伤性疾病、癌症、慢性神经退化、疼痛、偏头痛和心脏肥大。
• Imidazole-2-carboxamide derivatives as Raf kinase inhibitors
  申请人：SmithKline Beecham P.L.C.

  公开号：US07282500B2

  公开（公告）日：2007-10-16

  The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, use as Raf Kinase Inhibitors and treatment methods for neurotraumatic diseases and cancer.

  本发明涉及式(I)的化合物或其药学上可接受的盐、相应的制药组合物、用作Raf激酶抑制剂和治疗神经创伤性疾病和癌症的治疗方法。
• Imidazole derivatives as Raf kinase inhibitors
  申请人：SmithKline Beecham plc

  公开号：US07199137B2

  公开（公告）日：2007-04-03

  Novel compounds (I) and their use as pharmaceuticals particularly as Raf kinase inhibitors for the treatment of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine and cardiac hypertrophy wherein Ar is a group of formula a) or b).

  小说化合物（I）及其作为药物的用途，尤其是作为Raf激酶抑制剂用于治疗神经创伤性疾病、癌症、慢性神经退行性疾病、疼痛、偏头痛和心肌肥厚，其中Ar是公式a）或b）的一组。